{"id":28666,"date":"2014-08-19T08:59:57","date_gmt":"2014-08-19T12:59:57","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=28666"},"modified":"2014-08-19T09:06:10","modified_gmt":"2014-08-19T13:06:10","slug":"deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666","title":{"rendered":"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Biopharmaceutical company <strong>Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)<\/strong> had received a favorable comment from Deutsche Bank analyst on the improvement of its execution of clinical trial, which was one of the key concerns until recently.<\/p>\n<p style=\"text-align: justify;\"><strong>Positive Comment<\/strong><\/p>\n<p style=\"text-align: justify;\">The investment advisor\u2019s analyst, <a href=\"https:\/\/finance.yahoo.com\/news\/deutsche-bank-raises-achillion-price-122839835.html\" target=\"_blank\">Alethia Young,<\/a> viewed the recent appointment of a fresh CMO as increasing the management expertise. The analyst had also allayed concerns on clinical and management execution and said that they were showing signs of improvement. The brokerage base case assumed a 40% chance of success rate.<\/p>\n<p style=\"text-align: justify;\">Terming that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) remained a takeover target, Young said that every 10% of probability of success for the nuke or POS was valued around $5 &#8211; $6 a share. The analyst assumed the company\u2019s peak sales of $3 billion, i.e. 10% peak share, in 2018 with a 5% lower price point compared to <strong>Gilead Sciences, Inc. (NASDAQ:GILD)<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Deutsche Bank viewed Nuke as essential for competitive long-term course of therapy in HCV. Presently, Gilead Sciences, Inc. (NASDAQ:GILD) and <strong>Merck &amp; Co., Inc. (NYSE:MRK)<\/strong> were either in the market or in the development of nukes.<\/p>\n<p style=\"text-align: justify;\"><strong>Rating Of Stock<\/strong><\/p>\n<p style=\"text-align: justify;\">As a result of favorable factors, the brokerage had upgraded its rating on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares to Buy from Hold rating. The analyst was not content with the changes in rating alone and preferred to boost the price objective too.<\/p>\n<p style=\"text-align: justify;\">Deutsche Bank analyst Young had lifted his price target to $17 from $6 on the shares of Achillion Pharmaceuticals. The increase in price objective was significant by $11 or 183.3% from his previous price tag. The revised price target presents a potential upside reward of 78.2% from the Monday\u2019s closing price of $9.54.<\/p>\n<p style=\"text-align: justify;\"><strong>Stock Price<\/strong><\/p>\n<p style=\"text-align: justify;\">The stock has a 52-week low of $2.26 and a high of $10.10 reached on August 18. On Monday, the company\u2019s shares witnessed a trading volume of 16.9 million shares compared to the three-month-average volume of 7.17 million shares. On August 15 too, 21.9 million shares changed hands compared to 4.7 million, 2.9 million, 2 million, and 4.6 million volume in the preceding <a href=\"https:\/\/finance.yahoo.com\/q\/hp?s=ACHN+Historical+Prices\" target=\"_blank\">four days<\/a> of trading. The recent uptick in volume only suggests a fresh interest among interests to shop the stock ahead of any fresh developments, including a takeover proposal.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Biopharmaceutical company Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had received a favorable comment from Deutsche Bank analyst on the improvement of its [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":28667,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2990,3133,8063,1978,3626,1683,2991,1522,1123],"stock_ticker":[],"class_list":["post-28666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-achillion-pharmaceuticals-inc-nasdaqachn","tag-achillion-pharmaceuticals-inc","tag-alethia-young","tag-gilead-sciences-inc-nasdaqgild","tag-gilead-sciences-inc","tag-merck-co-inc-nysemrk","tag-nasdaqachn","tag-nasdaqgild","tag-nysemrk","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Biopharmaceutical company Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had received a favorable comment from Deutsche Bank analyst on the improvement of its [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-19T12:59:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-08-19T13:06:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"273\" \/>\n\t<meta property=\"og:image:height\" content=\"185\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving\",\"datePublished\":\"2014-08-19T12:59:57+00:00\",\"dateModified\":\"2014-08-19T13:06:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg\",\"keywords\":[\"Achillion Pharmaceuticals Inc (NASDAQ:ACHN)\",\"Achillion Pharmaceuticals Inc.\",\"Alethia Young\",\"Gilead Sciences Inc (NASDAQ:GILD)\",\"Gilead Sciences Inc.\",\"Merck &amp; Co Inc. (NYSE:MRK)\",\"NASDAQ:ACHN\",\"NASDAQ:GILD\",\"NYSE:MRK\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\",\"name\":\"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg\",\"datePublished\":\"2014-08-19T12:59:57+00:00\",\"dateModified\":\"2014-08-19T13:06:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg\",\"width\":273,\"height\":185},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666","og_locale":"en_US","og_type":"article","og_title":"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving - Wall Street PR","og_description":"Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Biopharmaceutical company Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had received a favorable comment from Deutsche Bank analyst on the improvement of its [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-19T12:59:57+00:00","article_modified_time":"2014-08-19T13:06:10+00:00","og_image":[{"width":273,"height":185,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving","datePublished":"2014-08-19T12:59:57+00:00","dateModified":"2014-08-19T13:06:10+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg","keywords":["Achillion Pharmaceuticals Inc (NASDAQ:ACHN)","Achillion Pharmaceuticals Inc.","Alethia Young","Gilead Sciences Inc (NASDAQ:GILD)","Gilead Sciences Inc.","Merck &amp; Co Inc. (NYSE:MRK)","NASDAQ:ACHN","NASDAQ:GILD","NYSE:MRK"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666","url":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666","name":"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg","datePublished":"2014-08-19T12:59:57+00:00","dateModified":"2014-08-19T13:06:10+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/ACH.jpg","width":273,"height":185},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/deutsche-bank-believes-achillion-pharmaceuticals-inc-nasdaqachn-execution-is-improving-28666#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=28666"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28666\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/28667"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=28666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=28666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=28666"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=28666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}